Dr. Rohrich's peptide therapy claims need more context

What did @rod.rohrich actually say?

The claim is specific: some peptides "were FDA-approved products" but pharmaceutical companies pulled them from the market because they weren't profitable. The implication is that compounding these peptides is therefore justified, because the underlying research and approval history still exists. That's a condensed argument with real parts to unpack.

The video references peptides that allegedly cleared FDA approval pathways, then got abandoned by commercial manufacturers. The suggestion is that compounded versions of these molecules inherit the safety credibility of those earlier approval studies. This is a popular argument in the peptide compounding space, and it deserves a direct look rather than a dismissal.

Does the science back this up?

Partly. There is a real category of drugs called "discontinued" FDA-approved medications, and some peptide-related compounds do fit this description. But the leap from "was once approved" to "compounding it is safe" skips several important steps.

Sermorelin is a real example. It received FDA approval for pediatric growth hormone deficiency in 1997 and was later discontinued by its manufacturer. It is now widely compounded. That much matches the narrative. BPC-157, which often comes up in these conversations, is a different story entirely. It has never received FDA approval and is not on the FDA-cleared discontinued list. The FDA placed BPC-157 on its Category 2 list in 2023, meaning it cannot be legally compounded by licensed pharmacies under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Lumping well-researched discontinued drugs together with unregulated research peptides as if they share the same regulatory standing is where this argument goes sideways.

What did they get wrong (or right)?

They got the basic concept right: drug discontinuation driven by commercial decisions is real and documented. Manufacturers do abandon approved drugs when margins disappear. The FDA's Discontinued Drug Product list confirms this happens across many drug classes, not just peptides.

But the claim that compounding "makes sense because they're well researched" conflates two separate things. Research quality and regulatory status are not the same as compounding legality or safety equivalence. A compounded peptide is not the same product as an FDA-approved drug, even if the molecule is identical. The FDA has said this explicitly. Compounded drugs lack the manufacturing standards, sterility verification, and pharmacokinetic data that approved products require. A 2022 FDA guidance document on compounding specifically warns against using prior approval history as a proxy for compounding safety. The video does not make this distinction, which is a meaningful omission given the audience size.

What should you actually know?

The peptide compounding space operates in a regulatory gray zone that is actively narrowing. The FDA's 2023 actions placed several popular peptides, including BPC-157 and TB-500, on lists that restrict or prohibit their compounding by licensed pharmacies. This affects access and legal standing regardless of what any individual study says about the molecule.

If you are interested in peptide therapy, the practical questions matter more than the philosophical argument about prior approvals. Is the compound coming from a licensed 503A or 503B pharmacy? Has it been tested for sterility and potency? Is a licensed physician supervising the protocol? Research from Goldenberg et al. (2021, Dermatologic Surgery) on GHK-Cu noted promising topical applications but also flagged that injectable formulations from compounders lack standardized dosing data. That gap between published research and clinical reality is where patients take on real risk. The argument that prior FDA studies confer safety to a compounded version does not hold up to regulatory or clinical scrutiny.